• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Infect Dis . Evaluation of Immunogenicity by Pseudovirus Neutralization Assays for Coronavirus Disease 2019 (COVID-19) Variants after Primary

tetano

Editor, Senior Moderator
Int J Infect Dis


. 2022 Feb 2;S1201-9712(22)00075-3.
doi: 10.1016/j.ijid.2022.01.068. Online ahead of print.
Evaluation of Immunogenicity by Pseudovirus Neutralization Assays for Coronavirus Disease 2019 (COVID-19) Variants after Primary and Booster Immunization


Hui Xie[SUP] 1 [/SUP], Xiaojing Wen[SUP] 1 [/SUP], Juan Li[SUP] 1 [/SUP], Weixin Chen[SUP] 1 [/SUP], Meng Chen[SUP] 1 [/SUP], Lichi Zhang[SUP] 1 [/SUP], Min Lv[SUP] 1 [/SUP], Shanshan Zhou[SUP] 1 [/SUP], Shuang Bai[SUP] 1 [/SUP], Wei Zhao[SUP] 1 [/SUP], Jian Wang[SUP] 1 [/SUP], Jiang Wu[SUP] 2 [/SUP]



Affiliations

Abstract

Objectives: To determine the status of immune responses after primary and booster immunization for coronavirus disease 2019 (COVID-19) variants and evaluate the differences in disease-resistance based upon titers of neutralizing antibodies (NAbs) against the variants.
Methods: Participants aged 18 - 59 y received two doses of inactivated COVID-19 vaccine, 14 days apart, and a booster dose after 12 m. Blood samples were collected before vaccination (baseline), 1 and 6 m after primary immunization, and at multiple instances within 21 d of booster dose. NAbs against the spike protein of Wuhan-Hu-1 and three variants were measured using pseudovirus neutralization assays.
Results: Out of 400 enrolled participants, 387 completed visits scheduled within 6 m of the second dose, and 346 participated received the booster dose in the follow-up research. After 1 m of primary immunization, geometric mean titers (GMTs) of NAbs peaked for Wuhan-Hu-1, while GMTs of other variants were < 30. After 6 m of primary immunization, GMTs of NAbs against all strains were < 30. After 3 d of booster immunization, GMTs were unaltered, seroconversion rates reached approximately 50% after 7 d, and GMTs of NAbs against all strains peaked at 14 d.
Conclusion: Two-dose of inactivated COVID-19 vaccine induced the formation of NAbs and memory-associated immune responses, and high titers of NAbs against the variants obtained after booster immunization may further improve the effectiveness of the vaccine.

Keywords: COVID-19 variant; inactivated COVID-19 vaccine; primary and booster immunization; pseudovirus neutralization assay.
 
Back
Top Bottom